A collaboration between SLG Hospitals and Ajeenkya DY Patil Healthcare will culminate in the inauguration of a 800-bed, multi-disciplinary medical facility in the city of Hyderabad.

Hospital prioritizes critical and urgent care, cardiology, and oncology, encompassing radiation oncology.

, and Administrator

2025 September 15 . 1:08 AM

1 min read

Multi-specialty hospital with 800 beds to be jointly established by SLG Hospitals and Ajeenkya DY... — Multi-specialty hospital with 800 beds to be jointly established by SLG Hospitals and Ajeenkya DY Patil Healthcare in Hyderabad

A collaboration between SLG Hospitals and Ajeenkya DY Patil Healthcare will culminate in the inauguration of a 800-bed, multi-disciplinary medical facility in the city of Hyderabad.

In the realm of healthcare, several significant developments have taken place in recent times.

Firstly, the Department for Promotion of Industry and Internal Trade (DPIIT) has entered into a Memorandum of Understanding (MoU) with Pfizer, a leading global biopharmaceutical company. This agreement aims to expedite the lab-to-market journey of healthcare products, potentially bringing innovative solutions to patients more quickly.

Separately, the Global Institute of Business Studies (GIBS) has announced its 10th Annual Conference. The date and location for this event, as well as the conference theme, have yet to be disclosed.

In the domain of healthcare services, ShardaCare Healthcity and Sharda Hospital have appointed Sandeep Dogra as their Group Chief Operating Officer (COO). The specifics of Mr. Dogra's role at these institutions have not been detailed.

Robotics are also making strides in the field of kidney-preserving cancer care, although the exact details of these advancements remain undisclosed.

Meanwhile, the World Health Organization (WHO) has not made any announcements or updates in relation to these developments.

Lastly, it's worth noting that the DPIIT, in collaboration with the Federation of Indian Chambers of Commerce & Industry (FICCI), has also signed an MoU to accelerate the lab-to-market pathway of health products. However, the specifics of this agreement and the inclusion of any particular products, such as rapid-acting insulin analogues or GLP-1 receptor agonists, in the Essential Medicines List (EML) have not been addressed.

These developments underscore the dynamic nature of the healthcare sector, with advancements in technology, business partnerships, and service delivery all contributing to the ongoing evolution of healthcare services.